What are the investment strengths of Ocular Therapeutix Inc (OCUL)?

Gross margin of 88.9% TTM demonstrates high-value drug economics once scaled - operating leverage potential is significant if pipeline succeeds Working capital of 337.7M provides operational flexibility; 7.9x current ratio buffers against short-term liquidity crises

What are the investment risks for Ocular Therapeutix Inc (OCUL)?

Operating loss of -250.8M TTM on 55.8M revenue (-449% margin) with no visibility to breakeven - binary pipeline dependency 2.8B market cap on 55.8M revenue requires massive pipeline success already priced in; P/B of 11x leaves no margin of safety

Ocular Therapeutix Inc

OCUL

—

Build a strategy around OCUL

Ocular Therapeutix Inc AI Insights

Informational only. Not investment advice.

As of 2025-12-10

Snapshot

R&D spend of 187.3M TTM is 336% of revenue (55.8M) - classic pre-commercial biotech burning cash on pipeline development[Research and Development TTM]
Cash runway of ~1.7 years (344.8M cash vs 199.4M FCF burn TTM) creates near-term financing risk[Cash and Equivalents]
P/S of 50.8x vs industry median 4.1x reflects binary pipeline optionality, not current fundamentals[P/S Ratio]

Watch Triggers

Cash and Equivalents: Falls below 200M or burn rate accelerates beyond 60M/quarter — Triggers dilutive financing; watch for S-3 filings or ATM announcements
Total Revenue TTM: Quarterly revenue inflection above 20M (vs ~14M current run rate) — Would signal commercial traction extending runway and reducing dilution risk
Research and Development TTM: R&D drops below 150M without pipeline setback — Could signal capital preservation mode or strategic pivot

Bull Case

Gross margin of 88.9% TTM demonstrates high-value drug economics once scaled - operating leverage potential is significant if pipeline succeeds

Gross Margin TTMGross Profit TTM

Working capital of 337.7M provides operational flexibility; 7.9x current ratio buffers against short-term liquidity crises

Working CapitalCurrent Assets

Bear Case

Operating loss of -250.8M TTM on 55.8M revenue (-449% margin) with no visibility to breakeven - binary pipeline dependency

Operating Income TTMOperating Margin TTM

2.8B market cap on 55.8M revenue requires massive pipeline success already priced in; P/B of 11x leaves no margin of safety

P/S RatioP/B RatioMarket Cap TTM

Bull vs Bear Balance

AI-generated sentiment analysis based on fundamental metrics and market conditions.

35%

Leverage OCUL's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.

Take Me to The Editor

Forward Thesis

Cash runway exhaustion by mid-2027 will force dilutive financing or partnership

1-3yhigh

FCF burn of -199.4M TTM with no path to profitability
R&D intensity unlikely to decrease pre-approval
77M debt limits additional leverage capacity

344.8M cash / 199.4M annual burn = 1.7 yearsDebt/equity 0.30 already elevated for loss-making biotechZero capital stock issuance in recent period

Valuation Context

Caveats

Public Strategies Rankings

See how Ocular Therapeutix Inc ranks across different investment strategies.

Leverage OCUL's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.

OCUL Fundamentals

Manufacturing → Chemical Manufacturing

Metric	Value	YoY Growth	Industry Percentile
Market Cap	$1.86B		—
Enterprise Value	$1.2B		—
P/E Ratio	0.00		—
Total Revenue - TTM	$51.95M	-18.5%	—
Earnings Per Share (diluted) - TTM	$-1.42		—
Operating Margin - TTM	-520%	-250.2%	—
Net Margin - TTM	-512%	-208.2%	—
Free Cash Flow - TTM	$-216.89M		—
Return on Common Equity - TTM	-54.9%	+40.4%	—
Beta 5Y (Monthly)	unknown		—

OCUL Dividend History

No dividends

OCUL Stock Splits

No stock splits

OCUL SEC Filings

Filing Date	Report Date	Report Type	Filing Link
02/05/26	12/31/25	10-K	0001104659-26-010664
11/04/25	09/30/25	10-Q	0001104659-25-105919
08/05/25	06/30/25	10-Q	0001558370-25-010177
05/05/25	03/31/25	10-Q	0001558370-25-006225
03/03/25	12/31/24	Unknown	0001558370-25-002000
11/14/24	09/30/24	10-Q	0001558370-24-015613
08/07/24	06/30/24	10-Q	0001558370-24-011202
05/07/24	03/31/24	10-Q	0001558370-24-007065
03/11/24	12/31/23	10-K	0001558370-24-002902
11/07/23	09/30/23	10-Q	0001558370-23-017989
08/07/23	06/30/23	10-Q	0001558370-23-013591
05/08/23	03/31/23	10-Q	0001558370-23-008510
03/06/23	12/31/22	10-K	0001558370-23-002908
11/07/22	09/30/22	10-Q	0001558370-22-016610
08/08/22	06/30/22	10-Q	0001558370-22-012623
05/09/22	03/31/22	10-Q	0001558370-22-007812
02/28/22	12/31/21	10-K	0001558370-22-002363
11/08/21	09/30/21	10-Q	0001558370-21-015029
08/09/21	06/30/21	10-Q	0001558370-21-010967
05/05/21	03/31/21	10-Q	0001558370-21-005914
03/11/21	12/31/20	10-K	0001558370-21-002813
11/05/20	09/30/20	10-Q	0001558370-20-012870
08/07/20	06/30/20	10-Q	0001558370-20-009817
05/08/20	03/31/20	10-Q	0001558370-20-005871
03/12/20	12/31/19	10-K	0001558370-20-002537
11/12/19	09/30/19	10-Q	0001558370-19-010684
08/07/19	06/30/19	10-Q	0001558370-19-007462
05/10/19	03/31/19	10-Q	0001558370-19-004776
03/07/19	12/31/18	10-K	0001558370-19-001659
11/07/18	09/30/18	10-Q	0001558370-18-008793
08/07/18	06/30/18	10-Q	0001558370-18-006598
05/08/18	03/31/18	10-Q	0001558370-18-004317
03/08/18	12/31/17	10-K	0001558370-18-001678
11/07/17	09/30/17	10-Q	0001558370-17-008385
08/08/17	06/30/17	10-Q	0001558370-17-006284
05/05/17	03/31/17	10-Q	0001558370-17-003598
03/10/17	12/31/16	10-K	0001558370-17-001627
11/09/16	09/30/16	10-Q	0001193125-16-763691
08/09/16	06/30/16	10-Q	0001193125-16-676019
05/10/16	03/31/16	10-Q	0001193125-16-584714
03/10/16	12/31/15	10-K	0001193125-16-499184
11/10/15	09/30/15	10-Q	0001193125-15-373490
08/10/15	06/30/15	10-Q	0001193125-15-284895
05/15/15	03/31/15	10-Q	0001193125-15-188936
03/20/15	12/31/14	10-K	0001193125-15-099288
11/12/14	09/30/14	10-Q	0001193125-14-407860
08/29/14	06/30/14	10-Q	0001193125-14-326864
07/25/14	03/31/14	424B4	0001193125-14-280620
07/25/14	12/31/13	424B4	0001193125-14-280620
11/12/14	09/30/13	10-Q	0001193125-14-407860
08/29/14	06/30/13	10-Q	0001193125-14-326864
07/25/14	03/31/13	424B4	0001193125-14-280620